Audio Journal of Oncology Podcast

podcast

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings...

News 200 recordings 2025 → today 3 episodes a week updated 10 days ago
Search in Audio Journal of Oncology Podcast →

All episodes

101–120 of 200
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings contributed by Lukas · Dec 18, 2025
ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke! “Financial Toxicity” is Often More Worrying than your Child’s Cancer contributed by Lukas · Dec 16, 2025
Daniel J Zheng MD, MHS, MSHP; ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke! “Financial Toxicity” is Often More Worrying than your Child’s Cancer contributed by Lukas · Dec 16, 2025
ASH 2025, Orlando: Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies contributed by Lukas · Dec 12, 2025
Peihua Lu MD and Robert Chiesa MD PhD; ASH 2025, Orlando: Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies contributed by Lukas · Dec 12, 2025
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer contributed by Lukas · Dec 1, 2025
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer contributed by Lukas · Dec 1, 2025
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer contributed by Lukas · Nov 24, 2025
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer contributed by Lukas · Nov 24, 2025
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy contributed by Lukas · Nov 19, 2025
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy contributed by Lukas · Nov 19, 2025
Erwei Song MD PhD, ESMO Berlin: Antibody Drug Conjugate Trastuzumab Resetecan Brings Early Significant Progression Free Survival Benefit in Patients with Previously Treated HER2+ Advanced Breast Cancer contributed by Lukas · Nov 14, 2025
Erwei Song MD PhD, ESMO Berlin: Antibody Drug Conjugate Trastuzumab Resetecan Brings Early Significant Progression Free Survival Benefit in Patients with Previously Treated HER2+ Advanced Breast Cancer contributed by Lukas · Nov 14, 2025
Andrew Clamp MD, PhD, ESMO Berlin: Weekly Dose-Dose Chemotherapy Brings Big Survival Benefit for Patients with High-Risk Ovarian Cancer contributed by Lukas · Nov 12, 2025
Andrew Clamp MD, PhD, ESMO Berlin: Weekly Dose-Dose Chemotherapy Brings Big Survival Benefit for Patients with High-Risk Ovarian Cancer contributed by Lukas · Nov 12, 2025
Nima Nabavizadeh MD; ESMO Berlin: Multi-Cancer Early Detection Test: PATHFINDER II study Finds Early Promise contributed by Lukas · Nov 7, 2025
Nima Nabavizadeh MD; ESMO Berlin: Multi-Cancer Early Detection Test: PATHFINDER II study Finds Early Promise contributed by Lukas · Nov 7, 2025
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study contributed by Lukas · Oct 31, 2025
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study contributed by Lukas · Oct 31, 2025
ESMO 2025; Christof Vulsteke MD PhD: Perioperative Enfortumab Vedotin Therapy With Pembrolizumab Boosts Event-Free and Overall Survival in Platinum-Ineligible Patients with Muscle-Invasive Bladder Cancer: KEYNOTE-905 study contributed by Lukas · Oct 30, 2025
page 6 of 10 «« ← Prev Next → »»

Charts

module · podcast

🇮🇳 #151 · +1 more

charted in 3 countriesFull rankings →

Activity

module · podcast

3 episodes · last 30 days

Fri 39Mon 29Thu 28

Episodes per week over the last six months.

About

module · podcast

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and pre...

Audio Medica News audiomedica.com RSS Apple